Tessari Eben 4
4 · Kiniksa Pharmaceuticals International, plc · Filed Dec 17, 2025
Insider Transaction Report
Form 4
Tessari Eben
CHIEF STRATEGY OFFICER
Transactions
- Exercise/Conversion
Class A Ordinary Share
2025-12-15$8.83/sh+6,000$52,980→ 28,714 total - Sale
Class A Ordinary Share
2025-12-15$41.56/sh−12,048$500,715→ 16,666 total - Exercise/Conversion
Share Option
2025-12-15−6,000→ 0 totalExercise: $8.83Exp: 2029-09-16→ Class A Ordinary Share (6,000 underlying)
Footnotes (3)
- [F1]This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024.
- [F2]This transaction was executed in multiple trades through a broker-dealer at prices ranging between $41.235 and $41.78. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- [F3]The option is fully vested and exercisable.